Canadian Intellectual Property Office (CIPO)’s proposal for fee adjustments is expected to come into force on January 1st, 2024.
We suggest reviewing your trademark portfolio for possible filings, renewals and other tasks that can be done in 2023 to benefit from cost savings.
The fee adjustments would apply to most of the fees for CIPO trademark services, including filing applications and renewing registrations. The proposal maintains the current fee structure, but would increase most fees by 25%, subject to exceptions. For a complete list, see CIPO’s Draft Fee Proposal. Below are some of the proposed fee increases, including the annual adjustment.
| Filing Fees* | Current fee | Proposed fee |
| 1st class: | $347.35 | $458.00 |
| Each additional class: | $105.26 | $139.00 |
| Renewal Fees* | ||
| 1st class: | $421.02 | $555.00 |
| Each additional class: | $131.58 | $173.00 |
| Assignments/Ownership Transfers | ||
| Filing fee | $100.00 | $125.00 |
| Statement of Opposition | ||
| Filing fee | $789.43 | $1,040.00 |
| Extensions of Time (where applicable) | ||
| Filing fee | $125.00 | $150.00 |
| Request S.45/Expungement Proceedings | ||
| Filing fee | $421.02 | $555.00 |
| Registration Fee | ||
| Filing fee | $210.51 | $277.00 |
*For online filings
CIPO states that the proposed fee adjustments will allow CIPO to address structural deficits, account for inflation, and keep pace with its international counterparts. Canada’s IP fees have not undergone comprehensive review since 2004, and Canada’s trademark registration fees have generally been lower than comparable IP offices in the US and EU.
While the fee increase is not yet finalized, it will likely be finalized for publication in the Canada Gazette, Part II later this year.
For any questions or additional information, please do not hesitate to contact us.
Related Publications & Articles
-
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More -
New USPTO rules will affect Canadian innovators not represented by a patent attorney or patent agent
Foreign filing licenses are a common but often overlooked requirement that can create headaches for patent applicants. Failure to obtain the appropriate authorization can lead to consequences ranging ...Read More -
Government of Canada launches consultation on expanding the geographical indications regime
On May 28, 2026, the Government of Canada launched a public consultation on the scope of the geographical indications (GIs) regime under the Trademarks Act. The consultation seeks stakeholders' views ...Read More
